3,123 press releases indexed under healthcare.
PDS Optical is pioneering a new front in Veteran healthcare with the launch of the Pulse on Digital Strain Survey. This first-of-its-kind initiative is specifically designed to uncover how modern screen time affects the vision health of the Veteran community, a population previously...
New data show 96% opioid abstinence rates among long-term patients as statewide overdose deaths begin to decline. RENTON, Wash., July 13, 2026 /PRNewswire-PRWeb/ -- Ideal Option, a national leader in outpatient medication-assisted treatment (MAT) for addiction to opioids, stimulants and...
Physician-scientist and immunology leader joins Cue as the company advances key clinical programs in allergic and autoimmune diseases Physician-scientist and immunology leader joins Cue as the company advances key clinical programs in allergic and autoimmune diseases
DALLAS, TX, July 13, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology company, today announced the U.S. launch of CT-RevitL™, the next-generation veterinary PBM laser therapy system from its Companion Animal Health business. CT-RevitL delivers enhanced clinical performance, greater mobility and a more intuitive treatment experience for veterinary teams and their patients.
New White Label Collection, Powered by WHSPR™ and Kleair™, Debuts with Revitalizing Scalp Serum and Scalp Screen Dry Shampoo SPF 45+ Sunscreen
Integrity Billing Company, a family-owned behavioral health revenue cycle management firm based in Palm Springs, Florida, is celebrating more than 10 years of serving treatment providers nationwide. The company is recognized for its ethical, U.S.-based billing operations, clinical...
(PR-inside.com) As glioblastoma continues to challenge the medical community, the Foundation unveils a new genomic testing lab, an advancing drug pipeline, and a sharper focus on accelerating personalized treatment for patients ahead of Glioblastoma Awareness Day on July 15. DURHAM, NC / ACCESS Newswire / July 13, 2026 / Over the past decade, the Glioblastoma Foundation has worked to advance research, educate patients and caregivers, support the glioblastoma community, and foster collaborations aimed at improving outcomes for individuals facing one of the most aggressive forms of cancer. As it enters its second decade, the Glioblastoma Foundation is expanding its efforts by building the ..
(PR-inside.com) Company Believes Industry Is Following the Early Regulatory Path That Fueled the Cannabis Market LAS VEGAS, NV / ACCESS Newswire / July 13, 2026 / Hypha Labs, Inc. (OTCQB:FUNI), a biotechnology company developing advanced mushroom production technologies, believes the rapidly expanding state-by-state adoption of psilocybin programs is creating a significant long-term opportunity for scalable manufacturing infrastructure. With Oregon, Colorado, and New Mexico now operating statewide psilocybin programs and more than two dozen states considering medical, research, or decriminalization legislation, Hypha Labs believes the industry is following a regulatory path similar to the early days of cannabis. "We believe the psychedelic industry is approaching ..
As glioblastoma continues to challenge the medical community, the Foundation unveils a new genomic testing lab, an advancing drug pipeline, and a sharper focus on accelerating personalized treatment for patients ahead of Glioblastoma Awareness Day on July 15.
IP portfolio reflects Autonomix’s neural sensing leadership in multi-billion-dollar denervation market
PURCHASE, N.Y., July 13, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and CEO, Lisa Ricciardi , has been invited to participate in a fireside discussion at the B. Riley Mind, Muscle & Vision Summit on July 16, 2026. During the discussion with analyst, William Wood, Ph.D., Ms. Ricciardi will review the status of the Company's ongoing START study as well as the planned initiation of a Phase 3 registrational study of zervimesine (CT1812) in dementia with Lewy bodies (DLB) psychosis.